Welcome to Scribd, the world's digital library. Read, publish, and share books and documents. See more
Download
Standard view
Full view
of .
Look up keyword
Like this
1Activity
0 of .
Results for:
No results containing your search query
P. 1
Novartis Pharmaceuticals et. al. v. Par Pharmaceutical

Novartis Pharmaceuticals et. al. v. Par Pharmaceutical

Ratings: (0)|Views: 68 |Likes:
Published by PriorSmart
Official Complaint for Patent Infringement in Civil Action No. 1:13-cv-01467-UNA: Novartis Pharmaceuticals Corporation et. al. v. Par Pharmaceutical Inc. Filed in U.S. District Court for the District of Delaware, no judge yet assigned. See http://news.priorsmart.com/-l8Yg for more info.
Official Complaint for Patent Infringement in Civil Action No. 1:13-cv-01467-UNA: Novartis Pharmaceuticals Corporation et. al. v. Par Pharmaceutical Inc. Filed in U.S. District Court for the District of Delaware, no judge yet assigned. See http://news.priorsmart.com/-l8Yg for more info.

More info:

Published by: PriorSmart on Aug 23, 2013
Copyright:Public Domain

Availability:

Read on Scribd mobile: iPhone, iPad and Android.
download as PDF, TXT or read online from Scribd
See more
See less

12/02/2014

pdf

text

original

 
 
ME1 16333346v.1
 
IN THE UNITED STATES DISTRICT COURTFOR THE DISTRICT OF DELAWARE
NOVARTIS PHARMACEUTICALSCORPORATION, NOVARTIS AG,NOVARTIS PHARMA AG, NOVARTISINTERNATIONAL PHARMACEUTICALLTD. and LTS LOHMANN THERAPIE-SYSTEME AGPlaintiffs,v.PAR PHARMACEUTICAL, INC.Defendant.X::::::::::::::XC.A. No. ____________
COMPLAINT FOR PATENT INFRINGEMENT
Plaintiffs Novartis Pharmaceuticals Corporation, Novartis AG, Novartis PharmaAG, Novartis International Pharmaceutical Ltd. and LTS Lohmann Therapie-Systeme AG(hereinafter “Plaintiffs”), for their Complaint against defendant Par Pharmaceutical, Inc. allegeas follows:
NATURE OF ACTION
1.
 
This is an action for patent infringement.
PARTIES
2.
 
Plaintiff Novartis Pharmaceuticals Corporation (“NPC”) is a corporationorganized and existing under the laws of the State of Delaware, having a principal place of business at 59 Route 10, East Hanover, New Jersey 07936.
 
 2
ME1 16333346v.1
 3.
 
Plaintiff Novartis AG (“Novartis AG”) is a corporation organized andexisting under the laws of Switzerland, having an office and place of business at Lichtstrasse 35,CH-4056 Basel, Switzerland.4.
 
Plaintiff Novartis Pharma AG (“Pharma AG”) is a corporation organizedand existing under the laws of Switzerland, having an office and place of business at Lichtstrasse35, CH-4056 Basel, Switzerland.5.
 
Plaintiff Novartis International Pharmaceutical Ltd. (“NIP”) is acorporation organized and existing under the laws of Bermuda, having an office and place of business at 131 Front Street, Hamilton HM12, Bermuda.6.
 
Plaintiff LTS Lohmann Therapie-Systeme AG (“LTS”) is a corporationorganized and existing under the laws of Germany, having an office and place of business atLohmannstraße 2, D-56626 Andernach, Germany.7.
 
On information and belief, defendant Par Pharmaceutical, Inc. (“Par”) is acorporation organized and existing under the laws of the State of Delaware, having an office andplace of business at One Ram Ridge Road, Spring Valley, New York 10977.
JURISDICTION AND VENUE
8.
 
This action arises under the patent laws of the United States of America.This Court has jurisdiction over the subject matter of this action under 28 U.S.C. §§ 1331,1338(a), 2201 and 2202.9.
 
On information and belief, Par is incorporated in Delaware and haspurposely availed itself of the rights and benefits of Delaware law and this Court.10.
 
On information and belief, Par is in the business of manufacturing,marketing, importing into the United States and selling pharmaceutical drug products, including
 
 3
ME1 16333346v.1
 generic drug products. On information and belief, Par directly or through its affiliates and agentsmarkets and sells drug products throughout the United States and in this judicial district, and haspurposely availed itself of the rights and benefits of Delaware law and this Court.11.
 
This Court has personal jurisdiction over Par by virtue of,
inter alia
, theabove-mentioned facts.12.
 
Venue is proper in this Court pursuant to 28 U.S.C. §§ 1391(b) and (c)and 28 U.S.C. § 1400(b).
CLAIM FOR RELIEF – PATENT INFRINGEMENT
13.
 
Plaintiff NPC holds an approved new drug application (“NDA”) No. 22-083 for Exelon
® 
Patch (rivastigmine transdermal system or extended release film) (4.6 mg/24 hr,9.5 mg/24 hr and 13.3 mg/24 hr dosage strengths), which patch contains the active ingredientrivastigmine. Exelon
® 
Patch (4.6 mg/24 hr and 9.5 mg/24 hr dosage strengths) was approved bythe United States Food and Drug Administration (“FDA”) on July 6, 2007, and Exelon
®
Patch(13.3 mg/24 hr dosage strength) was approved by the FDA on August 31, 2012. Exelon
®
Patchis indicated for the treatment of mild to moderate dementia of the Alzheimer’s type and mild tomoderate dementia associated with Parkinson’s disease. Exelon
® 
Patch (4.6 mg/24 hr, 9.5 mg/24hr and 13.3 mg/24 hr dosage strengths) is sold in the United States by Plaintiff NPC.14.
 
Rivastigmine is known chemically as (S)-N-ethyl-3-[(1-dimethylamino)ethyl]-N-methylphenyl-carbamate.15.
 
Plaintiffs Novartis AG and LTS are the owners of United States LettersPatent No. 6,335,031 (“the ‘031 patent”). The ‘031 patent was duly and legally issued onJanuary 1, 2002.

You're Reading a Free Preview

Download
scribd
/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->